Table 2.
Clinicopahtological characteristics of patients grouped according to mGPS
| Variable | mGPS 0 (n = 119) | mGPS 1 (n = 11) | mGPS 2 (n = 20) | P-value |
|---|---|---|---|---|
| Age (years) |
72 (43–91) |
74 (64–82) |
72 (51–79) |
0.14 |
| Sex (male/female) |
80/39 |
10/1 |
16/4 |
0.16 |
| HBsAg positive (%) |
12 (10) |
2 (18) |
5 (25) |
0.15 |
| HCVAb positive (%) |
76 (64) |
1 (9) |
7 (35) |
0 |
| AST (IU/l) |
53 (14–240) |
56 (17–238) |
113 (13–384) |
<0.0001 |
| ALT (IU/l) |
39 (10–202) |
53 (14–190) |
78 (8–157) |
0.02 |
| Total serum bilirubin (mg/dl) |
0.8 (0.3-3.1) |
0.7 (0.3-6.1) |
1.6 (0.3-8.3) |
0 |
| Albumin (g/dl) |
3.7 (2.1-5) |
3.9 (3.5-4.6) |
3.2 (2.2-3.4) |
<0.0001 |
| CRP (mg/dl) |
0.1 (0.1-0.9) |
1.5 (1.1-2.9) |
2.6 (1.1-18.8) |
<0.0001 |
| WBC (cells/mm3 ) |
5200 (1800–14900) |
5900 (3500–10600) |
5800 (3900–12400) |
0.07 |
| Platelet count (104/mm3 ) |
13.2 (2.8-30.9) |
25.3 (1.8-42.1) |
17.3 (8.7-44.3) |
0 |
| Prothrombin time (%) |
83 (38–100) |
95 (74–100) |
77 (45–97) |
0.01 |
| α-fetoprotein (ng/ml) |
22 (1.9-59597) |
77 (2–138011) |
144 (1.7-280600) |
0.05 |
| Child-Pugh grade (A/B/C) |
91/26/2 |
10/1/0 |
6/10/4 |
<0.0001 |
| CLIP score (0/1/2/3≧) |
41/43/24/11 |
3/0/3/5 |
0/7/1/12 |
<0.0001 |
| JIS score (0/1/2/3≧) |
18/43/41/17 |
0/4/3/4 |
0/1/6/13 |
<0.0001 |
| BCLC score (0/A/B/C,D) |
18/61/31/9 |
0/4/2/5 |
0/6/2/12 |
<0.0001 |
| Tumor stage (І,ІІ,ІІІ,ІV) |
21/52/41/5 |
0/4/3/4 |
1/4/4/11 |
<0.0001 |
| Maximal tumor diameter (mm) |
30 (7–200) |
110 (40–150) |
50 (10–130) |
<0.0001 |
| Tumor number (solitary/multiple) |
66/53 |
6/5 |
5/15 |
0.04 |
| Vascular invasion (absent/present) |
114/5 |
8/3 |
13/7 |
<0.0001 |
| Extrahepatic metastasis (absent/present) | 117/2 | 10/1 | 17/3 | 0.01 |
Abbreviaions: HBsAg = hepatitis B surface antigen; HCVAb = hepatitis C antibody; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
CRP = C-reactive protein; WBC = white blood cell count; ICG = indocyanine green dye retention rate at 15 minutes; CLIP = Cancer of the Liver Italian Program.
JIS = Japan Integrated Staging score; BCLC = Barcelona Clinic Liver Cancer; GPS = Glasgow Prognostic Score.